Better short-term survival with apalutamide versus darolutamide, but lots of unanswered qu ...

What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...

Recently, the research team led by Professor Jun Pang from the Department of Urology at The Seventh Affiliated Hospital of Sun Yat-sen University discovered that cyclin-dependent kinase 12 (CDK12) can ...

But an association with improved overall survival failed to reach statistical significance ...

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis. castration-resistant prostate cancer (CRPC) enhances glucose metabolism, shifts ...

The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...